ACE2 and prognosis of COVID-19. Insights from Bartter’s and Gitelman’s syndromes patients.

ACE2 and prognosis of COVID-19. Insights from Bartter’s and Gitelman’s syndromes patients.

Publication date: May 06, 2020

The relationship between Renin-Angiotensin system (RAS) and COVID-19 pandemic and, in particular, RAS as part of the CoV-2 infection process via Angiotensin Converting Enzyme 2 (ACE2), the entry point of SARS-CoV-2, has resulted in conflicting suggestions regarding how RAS and its role(s) should inform treating COVID-19. ACE inhibitors or angiotensin II (Ang)-type 1 receptor blockers (ARBs), in fact, have been suggested to be avoided as they potentially upregulate ACE2 and, conversely, there are suggestions that ARBs might be beneficial as SARS-CoV-2 causing ACE2 downregulation slows the Ang II conversion to the vasodilatory, anti-inflammatory, antioxidant and antiatherosclerotic Ang 1-7 , and the use of ARBs by blocking the excessive Ang II type-1 receptors activation, would be beneficial upregulating ACE2 activity and increasing Ang 1-7 levels. This article is protected by copyright. All rights reserved.

Concepts Keywords
ACE Inhibitors Infection
Angiotensin SARS
Antioxidant Branches of biology
Downregulation Medical specialties
Infection Endocrinology
Pandemic Enzymes
Prognosis Angiology
RAS Hypertension
Receptor Peptide hormones
Receptors Angiotensin
Renin Peptides
SARS ARBS
Vasodilatory Renin
ACE inhibitor

Semantics

Type Source Name
disease MESH syndromes
pathway KEGG Renin-angiotensin system
drug DRUGBANK Rasagiline
disease MESH infection
drug DRUGBANK Angiotensin II

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *